Ultrathin Biodegradable-Polymer Orsiro Drug-Eluting Stent Performance in Real Practice Challenging Settings.
Rigatelli G, Zuin M, Gianese F, Adami D, dell'Avvocata F, Barison S, Mazza A, Picariello C, Roncon L.
Cardiovasc Revasc Med. 2021 Sep;30:12-17. doi: 10.1016/j.carrev.2020.09.027. Epub 2020 Sep 23.
Efficacy and safety of drug-eluting stenting compared with bypass grafting in diabetic patients with multivessel and/or left main coronary artery disease.
Xin X, Wang X, Dong X, Fan Y, Shao W, Lu X, Xiao P.
Sci Rep. 2019 May 13;9(1):7268. doi: 10.1038/s41598-019-43681-x.
A randomised controlled trial of the sirolimus-eluting biodegradable polymer ultra-thin Supraflex stent versus the everolimus-eluting biodegradable polymer SYNERGY stent for three-vessel coronary artery disease: rationale and design of the Multivessel TALENT trial.
Hara H, Gao C, Kogame N, Ono M, Kawashima H, Wang R, Morel MA, O'Leary N, Sharif F, Möllmann H, Reiber JHC, Sabaté M, Zaman A, Wijns W, Onuma Y, Serruys PW.
EuroIntervention. 2020 Dec 18;16(12):e997-e1004. doi: 10.4244/EIJ-D-20-00772.
Comparison of a Simple Angiographic Approach With a Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Score-Based Approach for Left Main Coronary Artery Stenting: A Pooled Analysis of Serial PRECOMBAT (Premier of Randomized Comparison of Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease) Studies.
Lee PH, Lee JY, Lee CW, Kim SO, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Park SJ.
Circ Cardiovasc Interv. 2018 Jan;11(1):e005374. doi: 10.1161/CIRCINTERVENTIONS.117.005374.
Coronary artery bypass surgery versus percutaneous coronary intervention with drug-eluting stent implantation in patients with multivessel coronary disease.
Yang ZK, Shen WF, Zhang RY, Kong Y, Zhang JS, Hu J, Zhang Q, Ding FH.
J Interv Cardiol. 2007 Feb;20(1):10-6. doi: 10.1111/j.1540-8183.2007.00222.x.
Lesion impacts on long-term outcomes in patients implanted with bioresorbable vascular scaffold.
Wang YC, Kao HL, Wu CK, Lin MS, Chiang FT, Hwang JJ.
J Formos Med Assoc. 2022 Aug;121(8):1458-1465. doi: 10.1016/j.jfma.2021.10.012. Epub 2021 Nov 20.
Five-year clinical outcomes of drug-eluting stents according to on-label and off-label use.
Park KH, Kim U, Lee CH, Son JW, Park JS, Shin DG, Kim YJ, Cho JH.
Korean J Intern Med. 2016 Jul;31(4):678-84. doi: 10.3904/kjim.2015.045. Epub 2016 Mar 25.
Immediate and long-term outcomes of drug-eluting stent implantation for unprotected left main coronary artery disease: comparison with bare-metal stent implantation.
Gao RL, Xu B, Chen JL, Yang YJ, Qiao SB, Li JJ, Qin XW, Yao M, Liu HB, Wu YJ, Yuan JQ, Chen J.
Am Heart J. 2008 Mar;155(3):553-61. doi: 10.1016/j.ahj.2007.10.030.
Percutaneous coronary intervention in patients with end-stage renal disease.
Bocksch W, Fateh-Moghadam S, Mueller E, Huehns S, Waigand J, Dietz R.
Kidney Blood Press Res. 2005;28(5-6):275-9. doi: 10.1159/000090181. Epub 2006 Mar 7.
Effectiveness of sirolimus-eluting stent implantation for the treatment of ostial left anterior descending artery stenosis with intravascular ultrasound guidance.
Seung KB, Kim YH, Park DW, Lee BK, Lee CW, Hong MK, Kim PJ, Chung WS, Tahk SJ, Park SW, Park SJ.
J Am Coll Cardiol. 2005 Sep 6;46(5):787-92. doi: 10.1016/j.jacc.2005.06.009.
